Related Experiment Video
Updated: May 14, 2026
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Shenqi fuzheng injection improves cvb3-induced myocarditis via inhibiting traf6 expression
1Department of Integrated Traditional & Western Medicine, First Affiliated Hospital of FuJian Medical University, Fuzhou, China.
Insights
Shenqi Fuzheng injection (SQFZI) shows protective effects against viral myocarditis, a leading cause of heart failure. This study found SQFZI reduces cardiac inflammation and TRAF6 expression in Coxsackievirus B3-infected mice.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Viral myocarditis, often caused by Coxsackievirus B3 (CVB3), is a significant cause of heart failure in young adults.
- Current therapies for viral myocarditis and its associated inflammation remain limited.
- Shenqi Fuzheng injection (SQFZI) is commonly used for cardiovascular conditions, but its efficacy in viral myocarditis is not well-established.
Purpose of the Study:
- To investigate the protective potential of Shenqi Fuzheng injection (SQFZI) in a mouse model of Coxsackievirus B3 (CVB3)-induced viral myocarditis.
- To explore the effect of SQFZI on cardiac inflammation and TRAF6 expression during acute viral myocarditis.
Main Methods:
- An acute viral myocarditis model was established in 120 mice by intraperitoneal inoculation with CVB3.
- Body weight and mortality were monitored in infected mice.
- TRAF6 expression (mRNA and protein) in myocardial tissues was assessed using RT-PCR, Western blot, and immunohistochemistry.
- Serum enzyme activities (CK, CK-MB, LDH, AST) were measured.
Main Results:
- Coxsackievirus B3 infection significantly increased TRAF6 mRNA and protein expression in myocardial tissues.
- Elevated serum enzyme activities (CK, CK-MB, LDH, AST) were observed in CVB3-infected mice.
- SQFZI treatment markedly reduced CVB3-induced TRAF6 production.
- SQFZI administration alleviated the severity of viral myocarditis in the mouse model.
Conclusions:
- SQFZI demonstrates a protective role against Coxsackievirus B3-induced viral myocarditis.
- SQFZI may represent a novel therapeutic strategy for treating viral myocarditis by modulating cardiac inflammation and TRAF6 expression.
Abstract:
Viral myocarditis is a main cause of heart failure in young adults, which characterized by cardiac inflammation and caused by Coxsackievirus B3 (CVB3) infection. However, efficient therapies targeting inflammation and inflammatory response pathway are still elusive. Shenqi Fuzheng injection (SQFZI) is extensively applied in the cardiovascular diseases. But whether SQFZI may affect cardiac inflammation during acute viral myocarditis remains to be elucidated. The purpose of the present study was to investigate the potential protective effect of SQFZI on CVB3-induced myocarditis. Total of 120 mice were intraperitoneally inoculated with CVB3 to establish acute viral myocarditis model. For the CVB3-infected mice model, the body weight, mortality was observed. RT-PCR, western blot and immunohistochemistry methods were selected to detect the TRAF6 expression in myocardial tissues. We found that the expression of TRAF6 mRNA and protein were markedly and persistently increased during the progression of CVB3-induced myocarditis. The serum enzymes activity, including CK, CK-MB, LDH, AST, were also enhanced in CVB3-induced myocardial tissues. Notably, injection with SQFZI remarkably reduced CVB3-induced TRAF6 production and alleviated the severity of myocarditis. This study demonstrates the protective role of SQFZI against CVB3-induced myocarditis, which may explore a new therapeutic strategy for the treatment of viral myocarditis.
